INTRODUCTION

1
Biological synthesis has emerged as a highly promising alternative to traditional organic 2 synthesis for a variety of chemical compounds 1, 2 . One such compound, 3 3-hydroxy-γ-butyrolactone (3HBL), is widely used in the pharmaceutical industry as a chiral 4 building block for the statin class of cholesterol-reducing drugs such as Crestor® and Lipitor®, 5 as well as the antibiotic Zyvox® and the anti-hyperlipidemic medication Zetia® One impediment to broader adoption of biological systems for the production of 11 molecules such as this is the lack of established pathways for their synthesis. There are no 12 identified natural biochemical routes nor have engineered routes been previously reported for 13 the biosynthesis of 3HBL or its hydrolyzed acid form, 3,4-dihydroxybutyric acid (3,4-DHBA). 14 3HBL is currently produced as a specialty chemical and sells at a wholesale cost of 15 approximately $450/Kg. A continuous chemical synthesis process employing high pressure 16 hydrogenation of L-malic acid over a ruthenium-based catalyst in a fixed bed reactor has been 17 developed for the commercial synthesis of (S)-3HBL at a capacity of 120 tonnes per year 8, 9 ; 18 however, this process employs hazardous processing conditions and expensive catalyst and 19 purification processes. The various other chemical and chemoenzymatic routes developed for 20 3HBL synthesis 3 also suffer from similar disadvantages including the use of hazardous materials 21 and processing conditions 10, 11 , expensive starting materials, reagents and catalysts [11] [12] [13] [14] [15] , and 22 poor yield and formation of difficult to separate by-products 10, 12, 13, 16 , driving up the cost of the 1 product. Biosynthesis is expected to alleviate many of these problems and offer an elegant 2 solution towards economical production of this valuable chemical; however, this requires the 3 design of a novel biosynthetic pathway 17, 18 . 4
To design a pathway for the production of 3HBL, we focused on the hydrolyzed free 5 hydroxyacid form, 3,4-DHBA. Hydroxyacids as a class are versatile, chiral compounds that 6 contain both a carboxyl and a hydroxyl moiety, allowing for their modification into several 7 useful derivatives 19 and making them suitable for applications in the synthesis of antibiotics 20 , 8 β-and γ-amino acids and peptides 21, 22 , and as chiral synthetic building blocks 23 . 9
3-Hydroxyacids are also naturally produced as components of polyhydroxyalkanoate (PHA) 10 biopolymers 24 and can in turn be used to synthesize PHAs with novel properties 25, 26 . While 11 many substituent monomers have been incorporated into PHAs through modulation of 12 substrates provided in the culture medium 26, 27 , the number of monomers produced directly 13 from simple carbon sources is far smaller. Indeed, only 3-hydroxybutyrate (3HB) and 14 3-hydroxyvalerate (3HV) have been successfully produced at the gram per litre scale using 15 enzymes of the PHA biosynthetic pathway [28] [29] [30] . In these reports, 3HB or 3HV synthesis begins 16 with the condensation of two acetyl-CoA molecules or acetyl-CoA and propionyl-CoA, 17 respectively, through the action of a thiolase enzyme (PhaA or BktB). The β-keto group is 18 subsequently reduced to an alcohol by one of two 3-hydroxybutyryl-CoA dehydrogenases, PhaB 19 or Hbd, yielding the (R) or (S)-enantiomer, respectively. Lastly, production of the free acid 20 requires hydrolysis of the CoA moiety, which can be accomplished by the enzyme pair 21 phosphotransbutyrylase (Ptb) and butyrate kinase (Buk) 28, 31 , or by thioesterase II (TesB) 29, 32, 33 . 22
TesB is capable of hydrolyzing both enantiomers of 3HB-CoA, while the Ptb-Buk enzyme system 1 is specific to the (R)-enantiomer. Unlike acetyl-CoA, propionyl-CoA is not naturally produced 2 in E. coli in significant quantities. In Tseng et al 30 , exogenously supplied propionate was 3 intracellularly activated to propionyl-CoA using the previously described Ptb-Buk enzymes, 4 known to act reversibly to produce CoA-activated compounds 31 . 5
The successful direct production of 3HB and 3HV inspired the adaptation of this route to 6 produce more structurally diverse 3-hydroxyacids, especially 3,4-DHBA, thus creating a platform 7 pathway for biological synthesis from the core enzymatic elements described above (Fig. 1) . 8
The substrate range of the thiolase enzyme catalyzing the initial carbon-carbon bond-forming 9 reaction is a key element of the pathway, and BktB exhibits broader substrate range than 10 PhaA 34 . 3,4-DHBA synthesis using the 3-hydroxyacid pathway requires the condensation of 11 acetyl-CoA and glycolyl-CoA; however, the ability of the BktB thiolase to catalyze this reaction 12 was unknown. The pathway also requires the exogenous supply of glycolate, and there were 13 no reports describing production of glycolyl-CoA from glycolate. Thus, additional 14
CoA-activation systems were investigated. These included propionyl-CoA transferase (Pct), a 15 broad substrate-specificity enzyme from Megasphaera elsdenii 35, 36 that exchanges CoA 16 moieties between short-chain organic acids including acetyl-CoA, and propionyl-CoA synthetase 17 (PrpE) from Salmonella typhimurium LT2
37
, in addition to Ptb-Buk. We also investigated in 18 vivo synthesis of glycolate via the glyoxylate shunt to enable direct production of 3,4-DHBA 19 from glucose. Finally, we further explored extensibility of the pathway by feeding butyrate to 20 determine whether longer chain hydroxyacids could be produced and isobutyrate to examine 21 the potential for synthesis of branched chain hydroxyacids. While the different pathway 22 enzyme combinations tested showed considerable differences in in vivo activities in 1 synthesizing products from the supplied substrates, the combination consisting of Pct, BktB, 2 PhaB, and TesB was found to be most versatile and allowed synthesis of 5 novel products using 3 the platform, including 3,4-DHBA, 3HBL, 2,3-dihydroxybutyric acid (2,3-DHBA), 4 3-hydroxyhexanoic acid (3HH) and 3-hydroxy-4-methylvaleric acid (3H4MV). 5
6
RESULTS
1
Validation of the pathway enzymes through production of 3HV 2
Propionate is the natural substrate for Pct and PrpE, and the ability of Ptb-Buk to activate 3 propionate had been previously demonstrated 30 . To validate the functional expression of all 4 pathway enzymes and to gain insights into differences in their in vivo activities and specificities, 5
propionate and glucose were supplied to cultures of recombinant E. coli cells expressing one of 6 the three activators (pct, prpE, or ptb-buk), one of two 3-hydroxybutyryl-CoA reductases (phaB 7 or hbd), tesB, and bktB from their respective plasmids. 3HV was produced in all six 8 recombinant strains, confirming functional expression of all pathway genes (Fig. 2) . Among 9 the three activation enzymes, Pct resulted in the highest (S)-3HV titres, up to 18.00 ± 0.23 mM 10 (2130 ± 27 mg/L), when Hbd was utilized as the reductase (strain MG1), followed by Ptb-Buk 11 (strain MG3) and PrpE (strain MG2). In the case of (R)-3HV biosynthesis employing PhaB as 12 the reductase, all three activators were generally comparable, with up to 19.65 ± 1.81 mM 13 (2320 ± 213 mg/L) produced by strain MG4. The choice of reductase influenced both final 3HV 14 titres and 3HV production rates as strains utilizing PhaB (strains MG4-6) yielded more 3HV at a 15 faster rate than strains employing Hbd (strains MG1-3) ( Fig. 2 and Supplementary Fig. S1 ). 16 3HB is a by-product of the 3-hydroxyacid pathway since BktB retains high activity for the 17 condensation of two acetyl-CoA molecules 34 to produce acetoacetyl-CoA, the natural substrate 18 of both PhaB and Hbd. 3HB production levels were affected by the specific combination of 19 enzymes employed (Fig. 3) . In all of the experiments reported here, much less 3HB was 20 detected in strains utilizing Pct for CoA activation (Fig. 3 , strains MG1 and MG4) compared to 21 strains utilizing Ptb-Buk or PrpE. Pct can transfer the CoA moiety from acetyl-CoA to other 22 short organic acids 35 . This CoA transfer should significantly reduce intracellular acetyl-CoA 1 concentrations, making the second-order condensation of two acetyl-CoA molecules less likely 2 than the condensation of acetyl-CoA with another acyl-CoA (a first-order reaction with respect 3 to acetyl-CoA). Thus, strains utilizing Pct achieved the highest selectivity towards both (S)-3HV 4 and (R)-3HV (Fig. 2) , but produced the most acetate among the three activators examined (Fig.  5 3) as a direct consequence of the transferase reaction. 6 7 Production of 3,4-DHBA and 3HBL from glucose and glycolate 8
The platform pathway was designed to produce 3,4-DHBA from glycolate as a precursor 9 (Fig. 1) . In cultures supplemented with glycolate and glucose, only the pct-expressing strains, 10 MG1 and MG4, produced 3,4-DHBA, while strains expressing the activators prpE and ptb-buk 11 only synthesized 3HB and acetate ( Fig. 2 and Fig. 3) . Unexpectedly, these cultures also 12 produced small quantities of 3HBL. The lactone could be formed either due to direct 13 spontaneous lactonization of the 3,4-dihydroxybutyryl-CoA intermediate or from free 3,4-DHBA 14 upon equilibration under the culture conditions. If the former were true, then elimination of 15
TesB from the pathway should result in increased 3HBL synthesis. In strains not expressing 16 the tesB gene, 52% more 3HBL and 96% less 3,4-DHBA was produced (Supplementary Fig. S2) . and phaB in addition to bktB and tesB, synthesized up to 4.62 ± 0.33 mM (555 ± 52 mg/L) of 2 3,4-DHBA and 2.17 ± 0.15 mM (221 ± 15 mg/L) of 3HBL. The total 3,4-DHBA and 3HBL titres 3 estimated on a molar basis were about two fold higher with PhaB as a reductase than with Hbd 4 (Fig. 2) , indicating limitations associated with the activity of Hbd towards the non-natural 5 substrate 4-hydroxy-3-ketobutyryl-CoA. 6 7 Investigating a pathway side product: synthesis of 2,3-DHBA 8
In addition to 3,4-DHBA, strains MG1 and MG4 synthesized a second species that co-eluted 9 with 3,4-DHBA during HPLC analysis (Supplementary Fig. S3 ). This species eluted immediately 10 adjacent to the 3,4-DHBA ammonium adduct and was detected at the same m/z ratio of 138.1 11 during HPLC / MS analysis ( Supplementary Fig. S4 ). In the absence of glycolate or the 12 pathway enzymes, the product was not detected, indicating that the species was a structural 13 isomer generated by the platform pathway. 14 2,3-DHBA was one possible isomeric product, identical in mass to 3,4-DHBA, that we 15 4-hydroxy-3-ketobutyryl-CoA intermediate ( Fig. 4a and Supplementary Fig. S5a) . 20
Alternatively, the abstraction of an α-proton from glycolyl-CoA ( Fig. 4b and Supplementary Fig.  21 S5b) is expected to result in the synthesis of 2,3-DHBA via the 2-hydroxy-3-ketobutyryl-CoA 22 intermediate. The absence of a commercially available standard for 2,3-DHBA prevented the 1 direct confirmation of this hypothesis using HPLC/MS analysis. Thus, we used labelled 2 glycolate in which both of the hydrogen atoms on the α-carbon were replaced with deuterium 3 to investigate further (Fig. 4c) . As expected, a peak corresponding to the doubly deuterated 4 3,4-DHBA ammonium adduct (Fig. 4c) was observed at an m/z ratio of 140.1 that coincided with 5 the peak for the unlabelled 3,4-DHBA standard detected at an m/z of 138.1, confirming 6 3,4-DHBA synthesis in strain MG4 (Supplementary Fig. S4 ). Further, a peak corresponding to 7 the unknown species was detected at an m/z of 139.1. The loss of 1 mass unit relative to the 8 labelled 3,4-DHBA ammonium adduct was consistent with the mechanism for formation of 9 2,3-DHBA by the alternative Claisen condensation reaction ( Supplementary Fig. S6 ). 12 MG4 supplied with unlabeled glycolate was estimated to have synthesized 7.17± 0.54 mM 13 (860 ± 65 mg/L) of 2,3-DHBA (Fig. 2) . These titres were comparable to the total of 3,4-DHBA 14
Supplementary Methods and
and 3HBL (about 6.8 mM) produced in the same cultures and suggest a roughly equal selectivity 15 of BktB towards both isomers. While MG1 cultures also synthesized small quantities of 16 2,3-DHBA, these were too small to be quantified accurately using HPLC. 17 18
3,4-DHBA to 3HBL conversion by acid treatment 19
It is well documented that lactonization is acid-catalyzed 41 ; hence, the equilibrium 20 between 3,4-DHBA and 3HBL was expected to be governed by pH, amongst other factors. Glycolate can be directly synthesized in E. coli through the reduction of glyoxylate, 9 mediated by the endogenous glyoxylate reductase (YcdW). However, the glyoxylate shunt 10 ( Supplementary Fig. S8 ) is heavily regulated and is typically repressed during growth on glucose 11 or other carbon sources that are easily metabolized 42 . The glyoxylate shunt is regulated by 12 the phosphorylation state of isocitrate dehydrogenase (Idh), which is both phosphorylated and 13 de-phosphorylated by Idh kinase/phosphatase (AceK). Isocitrate lyase (AceA) catalyzes the 14 cleavage of isocitrate to glyoxylate and succinate. 15
We first examined the production of glycolate directly from glucose, using a minimal (M9) 16 medium in order to limit the available carbon sources and induce the glyoxylate shunt. To explore the potential of the pathway to incorporate longer chain, aliphatic substrates, 5 isobutyrate and butyrate were supplied to the culture medium to investigate the production of 6 the six carbon isomers 3-hydroxy-4-methylvalerate (3H4MV) and 3-hydroxyhexanoate (3HH), 7 respectively. While DHBA synthesis was only observed with Pct, all three CoA-activation 8 systems resulted in the production of 3H4MV, and all except PrpE could produce 3HH ( Fig. 2  9 and Fig. 3 , strains MG4-6). However, both 3H4MV and 3HH were detected only with the PhaB 10 reductase ( Fig. 2 and Fig. 3 , strains MG4-6). For 3H4MV, a fourth CoA-activation system was 11 tested, namely, B. subtilis Ptb-Buk. This system was chosen because of its association with 12 genes involved in branched-chain fatty acid synthesis, suggesting a preference for branched 13 acids such as isobutyrate 43 . The B. subtilis Ptb-Buk enzyme system resulted in 3H4MV titres 14 comparable to those obtained with the C. acetobutylicum homologs, but produced more 3HB 15 and less acetate (Supplementary Fig. S9 ). This suggests that the two Ptb-Buk homologs may 16 be equally efficient in activating isobutyrate, but the B. subtilis pair has lower activity with 17 acetyl-CoA resulting in lower acetate and higher 3HB, as the increased acetyl-CoA pool would 18 favour 3HB synthesis. Overall, 3H4MV titres were observed up to 2.27 ± 0.18 mM (300 ± 25 19 mg/L) in strain MG4 and 3HH titres up to 0.170 ± 0.04 mM (22.5 ± 5.9 mg/L) were achieved in 20 strain MG6. ). An ability to set carbon skeletons with unnatural substrates 15 represents an entirely new opportunity to envision and achieve targeted microbial synthesis of 16 value-added compounds. A recently published study reports carbon chain elongation for 17 targeted production of the unnatural branched alcohol, 3-methyl-1-pentanol; however, eight 18 other alcohols were produced as by-products 47 . Thus, our ability to produce the targeted 19 compounds through the formation of a new carbon-carbon bond while producing only two 20 related analogs (2,3-DHBA and 3HB) represents a significant achievement. stereoisomer is predominately used in the production of pharmaceuticals and high-value 10 compounds 3 . Identification and screening of hbd homologs could identify a reductase with 11 identical stereochemical preference but with an increased substrate tolerance for the 12 production of (R)-3,4-DHBA and (R)-3HBL. 13
A notable finding in this work was the observation of the alternative Claisen condensation 14 reaction to yield the 2,3-DHBA isomer. Since the reaction mechanism requires the abstraction 15 of an α-proton to initiate nucleophilic attack, we do not expect all molecular pairs to be equally 16 likely to form both isomers. Indeed, our inability to observe any alternative products in the 17 synthesis of 3HV is consistent with a previous report that found no activity with a BktB homolog 18 from Zoogloea ramigera (51% identity/68% similarity) in the thiolytic direction with the 19 branched 2-methylacetoacetyl-CoA isomer of β-ketovaleryl-CoA
40
. The unexpected 20 production of 2,3-DHBA is an exciting development because of the implication for other 21 molecular structures that could be formed using substrates with sufficiently electronegative 22 α-protons.
Additionally, the compound is of specific interest because of its utility as a 1 potential commercial target. Indeed, the 2,3-isomer is attractive as a monomer for use in the 2 synthesis of hyperbranched polymers 49 . 3
While our achievable titres of nearly 800 mg/L (S)
50
, while the Keasling group obtained 9 maximum amorphadiene titres of 112 mg/L in the first reported synthesis in an engineered 10 organism 51 . These low titres were observed in spite of the availability of natural pathways to 11 produce the target molecules. The latter example is especially encouraging given more recent 12 reports of 27.4 g/L amorphadiene produced in 2-L fed-batch reactors 52 . Indeed, we anticipate 13 that production of (S)-3,4-DHBA/3-HBL at comparable titres can result in a substantial reduction 14 in cost of goods for high-value applications such as pharmaceutical synthesis. 15
Taken together, the initial findings of novel molecules produced here point to three main 16 avenues for greatly enhancing the potential of this pathway to launch new commercial 17 bio-products. First, the full potential of the wild-type enzymes remains unknown from the 18 small subset of substrates that were screened. The broad substrate range of the thiolase for 19 catalyzing carbon-carbon bond forming reactions, an essential first step, enables one to 20 envision a wide array of novel compounds that could be produced and subsequently 21 transformed into products ranging from medicines to materials. Further characterization of 22 the promiscuous CoA-activating enzyme Pct may also lead to the use of this enzyme in 1 additional novel pathways that rely on CoA-containing compounds, including those involved in 2 fatty acid β-oxidation, Clostridial n-butanol biosynthesis, and the mevalonate-dependent 3 isoprenoid pathway. Second, improving upon the activities of the pathway enzymes, either 4 through screening for more active homologs or through protein engineering, should result in 5 both broader substrate range and higher production titres. Of particular interest is protein 6 engineering to influence product formation 53 , for example, to preference 3,4-over 2,3-DHBA 7 synthesis or to accelerate the alternative Claisen condensation, producing novel branched or 8 α-substituted molecules. Finally, production strains for hydroxyacid synthesis can be further 9 engineered to produce pathway substrates endogenously, as demonstrated here for the 10 production of DHBA and 3HBL from glucose and previously to produce 3HV from glucose or 11 glycerol as the sole carbon source 30 . Intracellular production of pathway substrates would 12 mitigate the cost and/or toxicity associated with the secondary carbon sources as well as 13 eliminate the need for substrate transport across the cellular envelope, potentially accelerating 14 production. Each of these approaches has the potential to further enhance the platform 15 pathway we present here as an efficient and sustainable avenue for the production of 16 value-added biochemicals. 
METHODS (1226 words)
1 Strains and plasmids (Table 1 ) 2 E. coli DH10B (Invitrogen, Carlsbad, CA) and ElectroTen-Blue (Stratagene, La Jolla, CA) were 3 used for transformation of cloning reactions and propagation of all plasmids. E. coli 4 MG1655(DE3 ΔendA ΔrecA) was described previously (as strain HCT10
30
) and was used as the 5 production host for hydroxyacid synthesis, as well as endogenous glycolate synthesis. 6
Genes from C. acetobutylicum ATCC 824 (ptb-buk and hbd), R. eutropha H16 (bktB and 7 phaB), E. coli K-12 (tesB, ycdW, and aceA-aceK), M. elsdenii (pct), S. typhimurium LT2 (prpE) and 8 B. subtilis 3610 (ptb and buk) were obtained by polymerase chain reaction (PCR) using genomic 9 DNA (gDNA) templates. All gDNAs were prepared using the Wizard Genomic DNA Purification 10
Kit (Promega, Madison, WI). Custom oligonucleotides (primers) were purchased for all PCR 11
amplifications (Sigma-Genosys, St. Louis, MO) as listed in Supplementary Table S2 . In all 12 cases, Phusion High Fidelity DNA polymerase (Finnzymes, Espoo, Finland) was used for DNA 13 amplification. Restriction enzymes and T4 DNA ligase were purchased from New England 14 Biolabs (Ipswich, MA). Recombinant DNA techniques were performed according to standard 15
procedures. 16
Two co-replicable vectors, pETDuet-1 and pCDFDuet-1 (Novagen, Darmstadt, Germany), 17
were used for construction of the 3-hydroxyacid pathway plasmids. Plasmid pHHD was 18 constructed from pKVS45 and enables expression of genes under the control of a tetracycline 19 inducible promoter (see Supplementary Methods). This plasmid is compatible with the Duet 20 vectors. The sites used for cloning the genes are underlined in Supplementary Table S2 . 21 PCR products were digested with the appropriate restriction enzymes and ligated directly into 22 similarly digested vectors. The ptb-buk fragment was generated by EcoRI and NotI digestion 1 of pCDF-PB 29 . The B. subtilis ptb and buk genes were cloned into an artificial operon using 2
Splicing by Overlap Extension (SOE) PCR
54, 55 to mimic the natural C. acetobutylicum ptb-buk 3 operon. The E.coli genes ycdW, aceA and aceK were similarly cloned into an artificial operon 4 to mimic the structure of the natural aceB-aceA-aceK operon in E. coli, with the ycdW gene 5 replacing aceB (see Supplementary Methods). Ligation reactions using pETDuet-1 and pHHD 6 as vectors were used to transform E. coli DH10B, while ligations using pCDFDuet-1 were used to 7 transform E. coli ElectroTen-Blue. One thiolase (bktB) and one of two 3-hydroxybutyryl-CoA 8 reductases (phaB and hbd) were cloned into pETDuet-1. The pCDFDuet-based plasmids 9 contained one of four CoA-activation genes (pct, ptb-buk, ptb-buk(Bs) and prpE) and one 10 thioesterase (tesB). The artificial operon ycdW-aceA-aceK was ligated into pHHD for 11 construction of the plasmid pHHD/ycdW-aceA-aceK that allows expression of enzymes for 12 endogenous glycolate synthesis upon induction with anhydrotetracycline (aTc). 13
All constructs were confirmed to be correct by restriction enzyme digestion and nucleotide 14 sequencing. Once all plasmids were constructed, one pETDuet-based plasmid and one 15 pCDFDuet-based plasmid were used to co-transform E. coli MG1655(DE3)ΔendAΔrecA (MG0) to 16 create hydroxyacid production strains For endogenous synthesis of glycolate, strain MG0-GP 17 was constructed by transforming MG0 with pHHD/ycdW-aceA-aceK. MG4 was transformed 18 with pHHD/ycdW-aceA-aceK to construct strain MG4-GDHP to study the direct synthesis of 19 glycolate, the two DHBAs and 3-HBL from glucose as a sole carbon source. 20 21 22
Culture conditions 1
Seed cultures of the recombinant E. coli strains (Table 1) were grown in LB medium at 30°C 2 overnight, and were used to inoculate 50 mL LB medium supplemented with 10 g/L glucose at 3 an inoculation volume of 2% in 250 mL flasks. Due to HPLC peak overlapping between 3HH 4 and LB components, 3HH biosynthesis was conducted in M9 minimal medium supplemented 5 with 10 g/L glucose where seed cultures were washed and re-suspended in M9 minimal 6 medium before inoculation. The shake flask cultures were then incubated at 30°C on a rotary 7 shaker at 250 RPM. Once the cells reached mid-exponential phase (when OD 600 reached 8 0.8-1.0), cultures were supplemented (final concentrations in parentheses) with IPTG (1 mM) 9
for induction of gene expression and one of the precursor substrates: neutralized propionate 10 (15 mM), butyrate (15 mM), isobutyrate (15 mM), and glycolate (40 mM). In all cases, culture 11 medium was supplemented with 50 mg/L ampicillin and 25 mg/L streptomycin to provide 12 selective pressure for plasmid maintenance. 13
The direct synthesis of glycolate, 2,3-DHBA, 3,4-DHBA and 3-HBL from glucose as a sole 14 carbon source in strains MG0-GP and MG4-GDHP was also conducted in M9 minimal medium to 15 promote glycolate synthesis via the glyoxylate shunt. MG0-GP cultures were supplemented 16 with 50 mg/L kanamycin and induced with aTc (250 ng/mL) while MG4-GDHP cultures were 17 supplemented with ampicilin (50 mg/L), streptomycin (50 mg/L) and kanamycin (30 mg/L) and 18 simultaneously induced with aTc (250 ng/mL) and IPTG (100 µM) in mid-exponential phase. 19 1 mL of culture was withdrawn every 24 h for up to 96 h for HPLC and HPLC/MS analysis. 20
Titres of 3-hydroxyacids reached a plateau at 72 h and there was essentially no difference in the 21 titres between 72 h and 96 h; accordingly, only the peak titres observed at 72 h were reported. 22
In general, experiments were performed in triplicates, and data are presented as the averages 1 and standard deviations of the results. 2 3
Metabolite analysis 4
Culture samples were pelleted by centrifugation and aqueous supernatant collected for 5 HPLC analysis using an Agilent 1200 series instrument with a refractive index detector (RID). 6
Analytes were separated using an Aminex HPX-87H anion-exchange column (Bio-Rad 7
Laboratories, Hercules, CA) and a 5 mM H 2 SO 4 mobile phase. Glucose, propionate, butyrate, 8 isobutyrate, glycolate, acetate, 3-hydroxybutyrate, 3-hydroxyvalerate, 3-hydroxyhexanoate, 9
and (S)-3-hydroxy-γ-butyrolactone were quantified using commercial standards by linear 10 interpolation from calibration of external standards. 11
Due to the absence of a commercially available standard, the 3,4-DHBA standard used for 12 HPLC analysis was prepared from (S)-3-hydroxy-γ-butyrolactone by saponification at 37˚C for 3 13 hours at pH > 10 using 10N sodium hydroxide. Complete conversion of (S)-3HBL to 14 (S)-3,4-DHBA (as confirmed by disappearance of the 3HBL peak on the HPLC time trace) was 15 observed during this treatment. Additionally, 3,4-DHBA and 2,3-DHBA synthesis was also 16 confirmed using HPLC/MS analysis on an Agilent 1100 series instrument equipped with 6120 17
Quadrapole MS with multi-mode source and an Aminex HPX-87H column with 25mM 18 ammonium formate as the mobile phase. The ammonium adduct of 3,4-DHBA was detected 19
at an m/z ratio of 138.1 to confirm 3,4-DHBA synthesis in the samples (Supplementary Fig. S4) . 20
The ammonium adduct of deuterium labelled 3,4-DHBA formed from deuterium labelled 21 2,2-D2-glycolic acid was detected at an m/z ratio of 140.1 while that of deuterium labelled 22 2,3-DHBA was detected at an m/z ratio of 139.1. Preparative chromatography was used to 1 co-purify 2,3-DHBA and 3,4-DHBA from the culture supernatants (see Supplementary 2 Methods). The identity of 3,4-DHBA and 2,3-DHBA was confirmed via 1 H, 13 
C, Heteronuclear 3
Single Quantum Coherence (HSQC), and Heteronuclear Multiple Bond Correlation (HMBC) NMR 4 using a Varian 500 MHz spectrometer (Supplementary Fig. S6 ). Due to co-elution of 2,3-DHBA 5 with 3,4-DHBA during separation of culture supernatants on the Aminex Column during HPLC 6 analysis, the 3,4-DHBA and 2,3-DHBA titres were estimated indirectly as described in the 7
Supplementary Information (see Supplementary Methods). 8 3H4MV was analyzed using HPLC/MS since a commercial standard was not available. A 9
Zorbax SB-Aq alkyl bonded phase column (Agilent Technologies, Wilmington, DE) with a 25 mM, 10 pH 3 ammonium formate mobile phase was used to separate 3H4MV for detection with an 11
Agilent 1100 series instrument equipped with either RID or 6120 Quadrapole MS with 12 multi-mode source. The commercial 3HH isomer was used with RID to estimate the 13 concentration of 3H4MV in supernatant samples. The ammonium adducts of 3H4MV and 3HH 14 were detected at an m/z of +150.1 to confirm the presence of the branched isomer 15 (Supplementary Fig. S10) 
9
Shake-flask production of chiral 3-hydroxyacids at 72h. The various recombinant strains are described 10 in Table 1 . Production of 3HV (red bars), 2,3-DHBA+3,4-DHBA+3HBL (green bars), 3H4MV (blue bars) and 11 3HH (pink bars) was achieved with supplementation of propionate, glycolate, isobutyrate and butyrate, 
16
synthesized by strain MG4. 2,3-DHBA was below the limit of quantitation for strain MG1.
17
Supplementary Table S1 shows the product yields on the supplied substrates. 
